Clinical Trial Update: Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating chimeric switch receptor–modified T cells in PD-L1–positive recurrent or metastatic malignant tumors; status is currently unkn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Chimeric Switch Receptor Modified T Cells

Snippet

Sponsor: China Meitan General Hospital | Conditions: Recurrent PD-L1+ Malignant Tumors, Metastatic PD-L1+ Malignant Tumors | Phase 1 | Status: UNKNOWN